L’utilisation chronique des glucocorticoïdes conduit généralement au développement d’une résistance aux glucocorticoïdes impliquant une modulation de l’expression de gènes impliqués dans l’inflammation ou la progression tumorale comme celui codant la MMP-9. L’expression de la MMP-9 est régulée par des mécanismes épigénétiques notamment l’acétylation des histones gouvernée par la balance HDAC/HAT (histone deacetyltransferase/histone acetyltransferase) et les micro-ARNs (miRs), mécanismes également impliqués dans les phénomènes de cortico-résistance. Cependant, les altérations épigénétiques survenant suite à un traitement chronique aux glucocorticoïdes et leurs répercutions sur l’expression de la MMP-9 ne sont pas encore clairement élucidés. L’objectif de notre étude consiste donc à déterminer le rôle des mécanismes épigénétiques dans le phénomène de résistance aux glucocorticoïdes à travers leur implication dans la régulation de l’expression de la MMP-9. Nous avons montré que l’exposition chronique aux glucocorticoïdes a perturbé, à la fois, la balance HDAC/HAT (favorisant une hyperacétylation des histones) et l’expression des miRs conduisant ainsi à une surexpression de la MMP-9. De plus, nous avons montré qu’en inhibant les HDACs par le MS-275 amplifiant ainsi le phénomène d’hyperacétylation des histones, le profil d’expression des miRs a été davantage perturbé, une perturbation qui s’est répercuté sur l’expression et la sécrétion de la MMP-9. En conclusion, nous avons montré que l’acétylation des histones et la modulation de l’expression des miRs pourraient agir en harmonie pour contrôler l'expression de la MMP-9 dans un contexte de résistance aux glucocorticoïdes. / Chronic use of glucocorticoids generally leads to the development of glucocorticoid resistance which involves a modulation of the expression of genes involved in inflammation or tumor progression as that encoding the MMP-9. MMP-9 expression is regulated by epigenetic mechanisms including histone acetylation governed by the balance HDAC / HAT (histone deacetyltransferase / histone acetyltransferase) and microRNAs (miRs). These mechanisms could be involved in the phenomena of cortico-resistance. However, epigenetic alterations occurring after chronic treatment with glucocorticoids and their repercussions on MMP-9 expression are not yet clearly understood. The aim of our study is to determine the role of epigenetic mechanisms in the phenomenon of glucocorticoid resistance through their involvement in the regulation of MMP-9 expression. We demonstrated that chronic exposure to glucocorticoids disrupted both the balance HDAC / HAT (favoring a histone hyperacetylation) and expression of miRs thus leading to an overexpression of MMP-9. In addition, we have shown that inhibiting HDACs by MS-275 thereby amplifying the phenomenon of histone hyperacetylation, the expression profile of miRs was more disturbed. This disturbance has affected MMP-9 expression and secretion. In conclusion, we have shown that histone acetylation and modulation of miRs expression of harmony miRs could act to control the expression of MMP-9 in a glucocorticoid resistance context.

Introduction.Le fibroblaste gingival (FG) est la cellule majoritaire de la gencive. Cette dernière fait face constamment aux agressions physico-chimiques, infectieuses et thermiques. L'une des caractéristiques de la gencive est sa réparation quasi-parfaite suite à une lésion ponctuelle. Ce n'est pas le cas pour d'autres tissus comme la paroi aortique. L'anévrisme aortique (AA) est un affaiblissement de la paroi aortique provoqué par une sécrétion exhaustive de métalloprotéases (MMPs) et en particulier de MMP-9. Il en résulte une dilatation de l'artère. Dans un modèle d'anévrisme de lapin, Durand et al (2012) avait montré que le FG pouvait ralentir, voire réparer un anévrisme. Dans notre étude, nous avons mis en place un modèle de coculture FG/AA d'origine humaine.Chez l'homme, la localisation de la pathologie peut être au niveau abdominal (Anévrisme Aortique Abdominale : AAA) ou thoracique (Anévrisme Aortique Thoracique : AAT). Etant donné que leur étiologie sont différentes, nous avons souhaité savoir s'il existait des différences selon les lésions. Cela nous permettrait en effet de mieux appréhender la prise en charge. Nous avons réalisé une étude comparative histo et physiopathologique entre les AAA et AAT. L'une des différences soulevée, est la présence d'un facteur infectieux au niveau des AAA. C'est un élément à prendre en compte pour une thérapie cellulaire et ainsi nous avons mis en culture des FG en présence de LPS, une endotoxine bactérienne.De plus pour approfondir notre travail sur l'utilisation du FG dans la thérapie cellulaire, nous avons initié une étude sur la plasticité de la sous-population souche des FG en étudiant, notamment leur orientation en cellules vasculaires (cellules endothéliales).Résultats/discussionLe FG, grâce à sa secrétion de TIMP-1, contribue à l'inhibition de la MMP-9 anévrismale. La sécrétion de MMP-9 est plus importante dans les lésions avec athérome (AAA) que celles sans athérome (AAT dans notre étude). Ceci est en corrélation avec la dégradation qui est plus importante dans les AAA que dans les AAT. La MMP-9 est une protéine sécrétée entre autre par les cellules inflammatoires. Une inflammation est présente dans les AAA et pas dans les lésions thoraciques. Ceci pourrait expliquer la différence de sécrétion de MMP-9 et donc de dégradation. Concernant l'origine de cette inflammation, nous avons recherché une cause infectieuse. Porphyromonas gingivalis (Pg) qui est une bactérie importante dans le développement de la parodontite (maladie inflammatoire des tissus de soutien de la dent) a été détectée dans les AAA. Une relation pathologique existerait entre la parodontite et l'AAA mais l'étude devrait être plus poussée pour connaître le mécanisme physiopathologique de ce phénomène. Toutefois, en ce qui concerne la thérapie cellulaire, le LPS qui est une endotoxine du Pg, n'affecte pas la capacité du FG à secréter du TIMP-1.En plus de la possibilité du FG à neutraliser la MMP-9 anévrismale, nous avons souhaité savoir si le FG avait des compétences de différentiation en cellule vasculaire. Un début d'exploration de la plasticité cellulaire de la souche multipotente de FG en cellule endothéliale, donnent des résultats préliminaires encourageants.Conclusion. Le FG pourrait être une cellule prometteuse pour une thérapie cellulaire de l'anévrisme aortique mais des explorations plus poussées sont encore nécessaires pour une telle application. / IntroductionGingival fibroblast (GF) is the main cell in gingiva which is constantly facing infectious, thermal and physico-chemical attacks. When a lesion occurs, the repair of gingiva is almost perfect. It is not the case for other tissues as the aortic wall. The aortic aneurysm (AA) is a pathologic expansion of aorta due to a weakening of the wall with an exhaustive secretion of metalloproteinases (MMPs) and particularly of MMP-9. In an aneurysm rabbit model, Durand and al (2012) have showed that GF could slow down or repair the aneurysm. In our study, we have established a co-culture model of human GF and human AA.For human, the location of the aortic disease may be at abdominal level (Abdominal Aortic Aneurysm: AAA) and thoracic level (Thoracic Aortic Aneurysm: TAA). Since the aetiologies are different, we wondered if histo and physiopathologic differences would existe between the both. It is impotant to know that for better supporting the disease. One of the difference between AAA and TAA is the presence of an infectious factor in AAA. This is an element to consider for cell therapy, so we studied the behavior of GF in presence of an endotoxin, the LPS.In addition, to further our work on the use of GF in cell therapy, we have initiated a study of the plasticity of the GF multipotente subpopulation including the differentiation into vascular cells (endothelial cell in particular).Results/DiscussionThanks to its TIMP-1 secretion, GF could contribute to the inhibition of MMP-9 activity in aneurysm. The secretion of MMP-9 in AA with atheroma (AAA) is highter than in TAA (without atheroma in our study). It is correlated to the degradation of AAA which is more important than the degradation of TAA. Inflammatory cells may secrete MMP-9. Inflammation is present in AAA and not in TAA. This, could explain the highter secretion of MMP-9 in abdominal lesion and also the degradation which is more important in AAA than in TAA. As for the origin of this inflammation, we researched an infectious factor. We isolated Porphyromonas gingivalis (Pg) in AAA, which might trigger or aggravate inflammation. This is an important bacterium in the development of periodontitis (inflammatory disease of the tissues supporting the tooth). A pathological relationship may exist between periodontitis and the AAA. The study should be further to know the pathophysiology of AAA related to Pg. But as regards the cell therapy, LPS, which is an endotoxin of Pg would not affect the secretion of TIMP-1 by the GF.In addition to its abilities to inhibate MMP-9 in aneurysm, we wondered if GF would be able to differentiate into vascular cell. An early exploration of GF multipotent subpopulation plasticity reveals a possible opportunity to go further in a the cell therapy.Conclusion.GF might be a promising cell for treating aortic aneurysm but further explorations are still necessary for its application.

Inflammatory processes mark all stages of atherogenesis. One of the key regulators of inflammation is the transcription factor nuclear factor kappa B (Nf-kb). Nf-kb is the general name for a whole family of dimeric transcription factors. One can distinguish between a classical and an alternative pathway with Rela/p50 (Nf-kb1) and Relb/p52 (Nf-kb2) representing the terminal transcription factors, respectively. Classical Nf-kb1 signaling has been associated with atherosclerotic lesion development many times, mainly because of its regulation of many pro-inflammatory proteins with an established role in atherogenesis. Recent studies provided evidence of crosstalk between classical Nf-kb1 and alternative Nf-kb2 signaling, implicating a potential role for Nf-kb2 in atherogenesis. The aim of the present study was to investigate the influence of Nf-kb2 on atherosclerotic lesion development in a knockout mouse model. Nfkb2 knockout (Nfkb2-/-) mice were generated on two different atherosclerosis sensible backgrounds, the Apoe- and Ldlr- deficient background. Quantification of atherosclerotic lesion development showed, that Nfkb2-/- mice developed significantly more atherosclerosis at the brachiocephalic artery than wild type controls, indicating a protective effect of Nf-kb2 on atherogenesis. Further expression analyses in bone marrow-derived macrophages (BMDM) revealed highly significant upregulation of matrix metalloproteinase 9 (Mmp9) in Nfkb2-/- mice. Overexpression of Mmp9 was associated with enhanced macrophage migration across extracellular matrix in vitro and an inflammatory plaque phenotype with advanced, macrophage-rich lesions. Accordingly, increased Mmp9 expression in Nfkb2-/- macrophages might have contributed to enhanced lesion development in these mice.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Hepatocyte Growth Factor (HGF)–induced Epithelial–Mesenchymal Transition (EMT) is a complex cellular pathway that causes epithelial cell scattering by breaking cell–cell contacts, eliminating apical–basal polarity, and replacing epithelial markers and characteristics with mesenchymal markers. Early EMT events include a brief period of cell spreading, followed by cell compaction and cell–cell contact breaks. A forward chemical genetics drug screen of 50,000 unique compounds measuring HGF–induced cell scattering identified 26 novel EMT inhibitors, including 2 proteolytic inhibitors. Here, we show that B5500–4, one of the EMT inhibitors from the screen, blocks HGF–induced EMT by a predicted blocking of the protease furin, in addition to secondarily blocking Beta–Secretase (BACE).We also show that MMP–12 and MMP–9 are required for HGF–induced EMT to progress. MMP–12 is required for cell contraction, and its inhibition produces a continuous cell spreading phenotype.We also demonstrate that both furin and BACE activity are required for HGF–induced EMT to proceed, but that they are involved in separate pathways. We show that BACE inhibition leads to a failure of cell spreading in early EMT, and that EphA2 is a member of this pathway. We also demonstrate that it is likely BACE2, and not BACE1 that is responsible for early cell spreading. Furin is also required for HGF–induced cell scattering, but does not play a role in the cell spreading process. These findings highlight the importance of proteolytic activity at the earliest stages of HGF–induced EMT.

No description available.

Perinatal hypoxic ischemic (HI) injury is a leading cause of long-term neurological complications in newborn babies. Matrix metalloproteinases (MMPs) are a family of endopeptidases that are capable of degrading the extracellular matrix (ECM) components. They are considered to be integral in many physiological processes. However, recently it has been demonstrated that the inappropriate activity of these proteases, particularly MMP-2 and 9, contribute to the pathogenesis of cerebral ischemia in the adult brain. Given that ECM disruption is frequently observed following injury to the developing brain, it is possible that MMPs play an important role in HI injury processes in the developing brain. Therefore, this thesis evaluated the hypothesis that MMP-2 and 9 participate in the pathophysiology of HI injury to the developing brain. Since ECM remodelling is a fundamental process during brain development it was important to first characterise the MMP-2 and 9 profiles in the normal developing forebrain. We demonstrated that MMP-2, which mainly was observed in cortical plate neurons, declined with age, thus indicating a potential role in the development and differentiation of the cortical plate. Conversely, MMP-9 was increased with age, particularly during active myelination, indicating that it may contribute in myelination. Secondly, we showed an upregulation of MMP-9 within the ischemic core during the early hours following HI injury, suggesting that MMP-9 may be involved in the development of delayed injury processes following hypoxic ischemia. On the contrary, MMP-2 was strongly upregulated during a later stage following injury surrounding the ischemic core possibly suggesting that it plays a role in wound repair processes. Thirdly, the profiles of tissue (tPA) and urokinase (uPA) plasminogen activators were characterised following HI injury since they are known to be major upstream activators of MMPs. uPA upregulation paralleled that of MMP-2 suggesting a function for uPA in wound repair processes following HI injury to the developing brain through activation of MMP-2. In contrast with uPA, tPA activity remained unaffected following injury at both ages. Finally, MMP-9 activity was inhibited using a very specific MMP-2/9 inhibitor, SB-3CT, to determine if the MMP-9 deficiency protects the developing brain from HI injury. The elevated MMP-9 activity following HI injury was attenuated by the SB-3CT treatment. Although SB-3CT failed to confer any significant neuroprotection, we recommend that further investigations are needed before discounting the role of MMP-9 during HI injury to the developing brain. In conclusion, we suggest that MMP-9 is induced following an insult to the developing brain potentially contributing to the delayed neuronal death whilst MMP-2 is involved in essential developmental, differentiation and wound repair processes.

Salivary duct carcinoma (SDC) is an uncommon neoplasm showing extensive local invasion and metastasis. Histologically it exhibits ductal differentiation without myoepithelial participation and resembles intraductal and invasive ductal carcinoma of the breast. This study investigates the incidence of intraductal disease within invasive SDC and characterizes the expression of CK19, COX-2, MMP-2, 9 and 11 in intraductal and invasive SDC. 21 conventional SDC, 8 SDC arising as carcinoma ex-pleomorphic adenoma (CaExPA), 2 pure low-grade intraductal SDC, 1 pure high-grade intraductal SDC and 1 intraductal SDC with de-differentiation were studied. The presence of intraductal tumor in SDC is relatively common (52.4%) but is not a prominent component. SDC tumor cells were strongly positive for CK19 and COX-2. MMP-2 and 9 expression showed no significant pattern. MMP-11 was expressed by fibroblasts surrounding invasive tumor and was significantly associated with lymph node positivity (p=0.02).

Salivary duct carcinoma (SDC) is an uncommon neoplasm showing extensive local invasion and metastasis. Histologically it exhibits ductal differentiation without myoepithelial participation and resembles intraductal and invasive ductal carcinoma of the breast. This study investigates the incidence of intraductal disease within invasive SDC and characterizes the expression of CK19, COX-2, MMP-2, 9 and 11 in intraductal and invasive SDC. 21 conventional SDC, 8 SDC arising as carcinoma ex-pleomorphic adenoma (CaExPA), 2 pure low-grade intraductal SDC, 1 pure high-grade intraductal SDC and 1 intraductal SDC with de-differentiation were studied. The presence of intraductal tumor in SDC is relatively common (52.4%) but is not a prominent component. SDC tumor cells were strongly positive for CK19 and COX-2. MMP-2 and 9 expression showed no significant pattern. MMP-11 was expressed by fibroblasts surrounding invasive tumor and was significantly associated with lymph node positivity (p=0.02).

Angiogenesis, the growth of new blood vessels, is a complex process involving several cell types and molecular signals. Excessive vascular growth is a problem in tumors, and insufficient vascularization hampers the function of transplanted insulin-producing pancreatic islets. Understanding the mechanisms behind blood vessel growth generates increased means to control angiogenesis. In this thesis a model of pancreatic islet transplantation to muscle has been used to study the involvement of leukocytes in the development of new vasculature. Transplantation of isolated islets of Langerhans into mouse muscle promoted revascularization of the grafts to a level comparable to native islets in the pancreas. The complete and functional vascular restoration resulted in improved blood glucose control compared to the clinical standard implantation site, the liver. This proved muscle as a transplantation site to be a clinically relevant option for the treatment of type 1 diabetes. The rapid islet revascularization process was found to be dependent on a distinct subset of neutrophils characterized by high expression of the chemokine receptor CXCR4 and the enzyme matrix metalloproteinase 9 (MMP-9). These cells were recruited to recently transplanted and hypoxic grafts by islet-secreted vascular endothelial growth factor A (VEGF-A). Leukocyte migration and interactions in the engraftment area were monitored using a high-speed confocal microscope followed by software tracking. New software was developed to visualize migration statistics. This tool revealed areas around the islet graft where neutrophil gathering coincided with sites of angiogenesis. Macrophages in the engraftment area positioned themselves close to the newly formed vasculature and were shown to have a stabilizing effect on the vessels. When macrophages were removed, no pericytes were recruited to the forming vasculature. The perivascular macrophages also began to express a pericyte marker when in the graft, suggesting a close relationship between these cell types or macrophage plasticity. In conclusion, this thesis presents muscle as a proangiogenic transplantation site for pancreatic islets for the treatment of type 1 diabetes, where the revascularization of the grafts was dependent on the recruitment and actions of specialized immune cells.